Back to top
more

Puma Biotechnology (PBYI)

(Real Time Quote from BATS)

$4.18 USD

4.18
128,901

-0.19 (-4.35%)

Updated May 21, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

    Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

    Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

      Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

      Puma Biotech (PBYI) delivered earnings and revenue surprises of 53.17% and 0.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More

        Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.

          What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

          On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

            Company News For Jun 27, 2018

            Companies In The News are: LEN,V,GE,PBYI

              Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote

              Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.

                Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

                The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

                  Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

                  Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.

                    Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?

                    On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.

                      Puma's Shares Fall This Year Post a Solid 2017: Here's Why

                      Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.

                        Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?

                        Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down

                          Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.

                            What's in the Cards for Puma (PBYI) This Earnings Season?

                            Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.

                              Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?

                              On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.

                                What's in the Cards for Merrimack (MACK) in Q4 Earnings?

                                Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.

                                  What's in Store for Endocyte (ECYT) This Earnings Season?

                                  Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.

                                    Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?

                                    Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.

                                      Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

                                      Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.

                                        Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

                                        In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.

                                          What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

                                          Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

                                            What to Expect From BioMarin (BMRN) This Earnings Season?

                                            BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

                                              What's in Store for Ligand (LGND) This Earnings Season?

                                              Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.

                                                What's in the Cards for Teva (TEVA) This Earnings Season?

                                                Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.

                                                  Puma, CANbridge Team Up to Commercialize Nerlynx in China

                                                  Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.